TrialReader


Metformin and Congenital Nephrogenic Diabetes Insipidus

NCT02460354 — Phase 1, Terminated, 2 participants, Emory University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI)

RegistryNCT02460354
StatusTerminated - Lack of effect in initial subjects
PhasePhase 1
Study typeInterventional; na, single group, masking: none, treatment
Enrollment2 (Actual)
SponsorEmory University (Other)
ConditionsDiabetes Insipidus
InterventionsMetformin (Drug)
Datesstart 2015-09-01, primary completion 2017-06-01, completion 2017-06-01, first posted 2015-06-02, last updated 2018-07-17
Locations3 sites in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Diabetes Insipidus All trials of Metformin

-Summary

The purpose of this study is to determine whether metformin can increase urine concentration (osmolality) and decrease the amount of urine in patients with congenital nephrogenic diabetes insipidus (NDI).

Expand all sections  ·  Collapse all

+Detailed description

Nephrogenic diabetes insipidus (NDI) is a genetic disease. Patients with this disease make large amounts of urine because their kidneys don't hold on to water. The large amount of urine means that patients need to urinate very frequently. They are also at increased risk for dehydration if they don't drink enough. The large amount of urine can sometimes damage their bladders and kidneys. There are some medicines that may help these patients urinate less, but they are not very effective. There is evidence in animal studies that a medication called metformin may help patients with NDI urinate less.

+Arms and interventions

ArmTypeInterventionsDescription
MetforminExperimentalDrug: MetforminSubjects with congenital nephrogenic diabetes insipidus (NDI) will receive one metformin 500 mg pill orally
  • Metformin (Drug), also known as Glumetza, Fortamet, Glucophage, Riomet: Metformin 500 mg pill dispensed once orally

+Outcome measures

Primary outcomes

  • Change in mean urine osmolality [Baseline, 7 hours]: Urine osmolality is a measure of urine concentration. Urine osmolality will be measured using a Wescor vapor pressure osmometer. A normal range for urine osmolality is approximately 500-850 mOsm/kg water. Change is the difference in average osmolality from baseline to 7 hours.

Secondary outcomes

  • Change in mean urine volume [Baseline, 7 hours]: Urine volume is a measure of fluid balance. Change from baseline in average volume of urine collected from baseline to 7 hours.

+Eligibility

Sex: Male, ages: 18 Years to any

Inclusion Criteria:

* Males with a documented mutation in the vasopressin type 2 receptor (V2R)
* Willing to provide consent and/or assent as appropriate
* Capable of providing urine samples as dictated by the protocol

Exclusion Criteria:

* Urinary incontinence
* Subjects who have heart disease, liver disease, diabetes, cancer, or other significant disease other than Nephrogenic Diabetes Insipidus (NDI)
* Subjects with significant renal dysfunction (defined as a calculated glomerular filtration rate (GFR) <80 ml/min/1.73 m\^2)
* Subjects with acquired NDI

+Locations (3)

FacilityCityCountryStatus
Childen's Healthcare of AtlantaAtlanta, GeorgiaUnited States
Emory University Hospital - Atlanta Clinical and Translational Science Institute (ACTSI)Atlanta, GeorgiaUnited States
Emory University HospitalAtlanta, GeorgiaUnited States

+Investigators

My Notes